Cellular and genetic therapies for haemophilia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary. Haemophilia continues to be a prime target for a variety of gene and cell‐based therapies. Pre‐clinical successes in both mouse and dog models of the disease have been documented with a variety of approaches over the past decade, and there have now been six small clinical trials of gene transfer in haemophilia. To date, the only significant adverse events documented in these trials have been related to host immune responses, indicating that immunologic barriers continue to represent the major obstacle to achieving success of gene transfer in humans. Despite these challenges, new strategies are being explored with novel serotypes of viral vectors and with the use of transient periods of immunosuppression to attenuate the immune response to the vector and transgene product following gene delivery. Two new clinical trials, both using AAV vectors, will likely start within the next year, and additional large animal pre‐clinical studies using other viral vector‐mediated approaches for gene transfer are expected in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
Self-citationSnyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Themis, M., Waddington, S. N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., Gregory, L. G., Nivsarkar, M., Themis, M., Holder, M. V., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.358 · Cited by 243
Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173
Cited by
Niemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Self-citationA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Coutu, D. L., Yousefi, A., & Galipeau, J. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22296 · Cited by 65
“…are frequent), they are caused by deficiencies in plasmatic proteins circulating systemically (coagulation factors VIII and IX for hemophilias A and B, respectively) and neither protein requires tissue-specific expression and can thus be delivered ectopically [Lillicrap et al., 2006].”
Background
Metadata
- Authors
- LILLICRAP, D., VANDENDRIESSCHE, T., & HIGH, K.
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 2006-04-27
- Volume
- 12
- Issue
- s3
- Pages
- 36-41
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W2109215179
- Cited by
- 45
- References
- 6
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cellular and genetic therapies for haemophilia. https://app.cochat.ai/papers/10.1111/j.1365-2516.2006.01259.x
- The paper
- LILLICRAP, D., VANDENDRIESSCHE, T., & HIGH, K. (2006). Cellular and genetic therapies for haemophilia. Haemophilia. https://doi.org/10.1111/j.1365-2516.2006.01259.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.